VJHemOnc is committed to improving our service to you

VJVirtual | MUK Nine study: what about tolerability?

VJHemOnc is committed to improving our service to you

Matthew Jenner

Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, highlights the tolerability observed in the UKMRA OPTIMUM (MUK Nine) study. This study looked at tailoring treatment for patients with high-risk newly diagnosed multiple myeloma. These data were submitted as an abstract to the BSH 2020 meeting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter